• Apellis Pharmaceuticals (NasdaqGS:APLS) reports its first full year of profitability for 2025 after prior years of losses.
• The company highlights contributions from the commercialization of EMPAVELI and SYFOVRE to this financial turnaround.
• Apellis initiates new pivotal trials in its pipeline and starts a Phase 2 clinical trial for geographic atrophy.
• The company receives a regulatory milestone payment following EMA approval of Aspaveli.

Apellis focuses on therapies that target the complement system, a core part of the immune response, with EMPAVELI and SYFOVRE already in the market. For investors tracking drug developers tied to rare disease and ophthalmology trends, a move to full year profitability can change how the business profile is viewed. The combination of commercial products and an advancing pipeline gives you multiple operational levers to watch, rather than a single product story.

With fresh pivotal trials underway and a Phase 2 program in geographic atrophy, clinical outcomes and regulatory decisions could shape how Apellis allocates capital over the next few years. The EMA milestone payment for Aspaveli also adds another source of cash inflow tied to regulatory progress, a factor some investors use when assessing funding needs and execution risk for a company like Apellis.

Stay updated on the most important news stories for Apellis Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Apellis Pharmaceuticals.

Quick Assessment

• ✅ Price vs Analyst Target: At US$21.42 vs a consensus target of about US$33.68, the price sits roughly 36% below analyst expectations.
• ✅ Simply Wall St Valuation: Simply Wall St estimates the shares trade about 80.8% below its fair value, flagging it as undervalued.
• ❌ Recent Momentum: The 30 day return is about 2.6% lower, so the share price has recently pulled back.

There is only one way to know the right time to buy, sell or hold Apellis Pharmaceuticals. Head to Simply Wall St's company report for the latest analysis of Apellis Pharmaceuticals's Fair Value.

Key Considerations

• 📊 First full year of profitability, supported by EMPAVELI and SYFOVRE, means the story now includes both revenue scale and positive earnings.
• 📊 Keep an eye on the P/E of about 122x and upcoming clinical and regulatory readouts, as these can influence whether current pricing and forecasts stay aligned.
• ⚠️ One flagged risk is recent insider selling over the past three months, which some investors watch alongside new profit and pipeline headlines.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Apellis Pharmaceuticals analysis. Alternatively, you can check out the community page for Apellis Pharmaceuticals to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.